Tirzepatide’s cardiovascular effects in clinical practice - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 4 min

Share

  • 1

    Tirzepatide is associated with a lower 1-year risk of major adverse cardiovascular events compared to sitagliptin in patients with type 2 diabetes.

  • 2

    The study analyzed data from 52,971 patients aged 40 and older who initiated tirzepatide or sitagliptin between May 2022 and May 2025.

  • 3

    At 1 year, the weighted risk of major adverse cardiovascular events was approximately 3% for tirzepatide and 4% for sitagliptin.

  • 4

    Tirzepatide was linked to fewer infection-related hospital admissions and lower infection-related mortality compared to sitagliptin.

  • 5

    The study's limitations include a relatively short follow-up period and potential residual confounding affecting mortality findings.

Original Source(s)

Tirzepatide’s cardiovascular effects in clinical practice

  • by Kathryn Wighton

  • August 28, 2026

Related Content

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Tree Canopy Gains Linked to Lower Mortality

The association was most pronounced in Chicago’s hottest neighborhoods, where canopy losses were linked to higher predicted mortality.

Left ventricular longitudinal function and hyperkinetic profile: a new echo world to explore?